<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66398">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241486</url>
  </required_header>
  <id_info>
    <org_study_id>205025</org_study_id>
    <nct_id>NCT02241486</nct_id>
  </id_info>
  <brief_title>Sublingual Fentanyl and Procedural Burn Pain</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Cross-over Trial of Sublingual Fentanyl Spray (Subsys) and Oral Morphine for Procedural Wound Care in Adult Patients With Burn Injury Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of sublingual fentanyl spray
      (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn
      injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of sublingual fentanyl spray
      (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn
      injury. It will be compared with a standard treatment regimen of oral morphine. The
      hypothesis is that the fentanyl spray will be more effective for the treatment of procedural
      pain in patients with burn injury.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No funding source.
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>60 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects - nausea, vomiting, pruritis, sedation, respiratory depression</measure>
    <time_frame>60 min</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Burn Pain</condition>
  <arm_group>
    <arm_group_label>Sublingual Fentanyl Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Fentanyl Spray</intervention_name>
    <arm_group_label>Sublingual Fentanyl Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject capable of giving consent

          -  Age 18-65

          -  Total burn surface area greater than or equal to 5%

          -  Opioid tolerant

          -  BMI less than or equal to 35

        Exclusion Criteria:

          -  Subjects with cognitive or psychiatric impairment that would preclude study
             participation or compliance with protocol

          -  Allergy to fentanyl, morphine, naloxone

          -  Pregnancy, intent to become pregnant or lactating

          -  Evidence of burn injury to oral mucosa

          -  Active illicit drug use or illicit drug abuse history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph R Holtman Jr, MD Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Anesthesiology Loyola University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center Burn Unit</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Joseph Holtman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Burn pain</keyword>
  <keyword>Procedural pain</keyword>
  <keyword>Sublingual fentanyl</keyword>
  <keyword>Morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
